메뉴 건너뛰기




Volumn 14, Issue 3, 2012, Pages

BOLERO-2 - will this change practice in advanced breast cancer?

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; EVEROLIMUS; EXEMESTANE; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TEMSIROLIMUS; TRASTUZUMAB; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MTOR PROTEIN, HUMAN; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

EID: 84862494067     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3126     Document Type: Note
Times cited : (8)

References (15)
  • 1
    • 11244296162 scopus 로고    scopus 로고
    • Mechanisms of tamoxifen resistance
    • 10.1677/erc.1.00776, 15613444
    • Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004, 11:643-658. 10.1677/erc.1.00776, 15613444.
    • (2004) Endocr Relat Cancer , vol.11 , pp. 643-658
    • Ring, A.1    Dowsett, M.2
  • 2
    • 43249130208 scopus 로고    scopus 로고
    • Double-blind, randomised placebo controlled trial of fulvestrant compared with exemestane after prior non-steroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor positive advanced breast cancer: results form EFECT
    • 10.1200/JCO.2007.13.5822, 18316794
    • Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M. Double-blind, randomised placebo controlled trial of fulvestrant compared with exemestane after prior non-steroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor positive advanced breast cancer: results form EFECT. J Clin Oncol 2008, 26:1664-1670. 10.1200/JCO.2007.13.5822, 18316794.
    • (2008) J Clin Oncol , vol.26 , pp. 1664-1670
    • Chia, S.1    Gradishar, W.2    Mauriac, L.3    Bines, J.4    Amant, F.5    Federico, M.6    Fein, L.7    Romieu, G.8    Buzdar, A.9    Robertson, J.F.10    Brufsky, A.11    Possinger, K.12    Rennie, P.13    Sapunar, F.14    Lowe, E.15    Piccart, M.16
  • 3
    • 0042232592 scopus 로고    scopus 로고
    • Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation
    • 10.1074/jbc.M305226200, 12775708
    • Martin LA, Farmer I, Johnston SR, Ali S, Marshall C, Dowsett M. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 2003, 278:30458-30468. 10.1074/jbc.M305226200, 12775708.
    • (2003) J Biol Chem , vol.278 , pp. 30458-30468
    • Martin, L.A.1    Farmer, I.2    Johnston, S.R.3    Ali, S.4    Marshall, C.5    Dowsett, M.6
  • 4
    • 0032887942 scopus 로고    scopus 로고
    • Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer
    • 10.1677/erc.0.0060373, 10516852
    • Nicholson RI, McClelland RA, Robertson JF, Gee JM. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 1999, 6:373-387. 10.1677/erc.0.0060373, 10516852.
    • (1999) Endocr Relat Cancer , vol.6 , pp. 373-387
    • Nicholson, R.I.1    McClelland, R.A.2    Robertson, J.F.3    Gee, J.M.4
  • 5
    • 0035971181 scopus 로고    scopus 로고
    • Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance
    • 10.1074/jbc.M010840200, 11139588
    • Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001, 276:9817-9824. 10.1074/jbc.M010840200, 11139588.
    • (2001) J Biol Chem , vol.276 , pp. 9817-9824
    • Campbell, R.A.1    Bhat-Nakshatri, P.2    Patel, N.M.3    Constantinidou, D.4    Ali, S.5    Nakshatri, H.6
  • 6
    • 34548537574 scopus 로고    scopus 로고
    • A phase II placebo-controlled trial of neo-adjuvant anastrozole alone or with gefitinib in early breast cancer
    • 10.1200/JCO.2006.09.6578, 17679728
    • Smith IE, Walsh G, Skene A, Llombart A, Mayordomo JI, Detre S, Salter J, Clark E, Magill P, Dowsett M. A phase II placebo-controlled trial of neo-adjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol 2007, 25:3816-3822. 10.1200/JCO.2006.09.6578, 17679728.
    • (2007) J Clin Oncol , vol.25 , pp. 3816-3822
    • Smith, I.E.1    Walsh, G.2    Skene, A.3    Llombart, A.4    Mayordomo, J.I.5    Detre, S.6    Salter, J.7    Clark, E.8    Magill, P.9    Dowsett, M.10
  • 10
    • 73949105921 scopus 로고    scopus 로고
    • Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results form the randomized TAnDEM study
    • 10.1200/JCO.2008.20.6847, 19786670
    • Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, Révil C, Jones A. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results form the randomized TAnDEM study. J Clin Oncol 2009, 27:5529-5537. 10.1200/JCO.2008.20.6847, 19786670.
    • (2009) J Clin Oncol , vol.27 , pp. 5529-5537
    • Kaufman, B.1    Mackey, J.R.2    Clemens, M.R.3    Bapsy, P.P.4    Vaid, A.5    Wardley, A.6    Tjulandin, S.7    Jahn, M.8    Lehle, M.9    Feyereislova, A.10    Révil, C.11    Jones, A.12
  • 12
    • 79951814007 scopus 로고    scopus 로고
    • TAMRAD: a GINECO randomized phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI)
    • Abstract S1-6
    • Bachelot T, Bourgier C, Cropet C, Guastalla J-P, Ferrero J-M, Leger-Falandry C, Soulie P, Eymard J-C, Debled M, Spaeth D, Legouffe E, Delozier T, El Kouri C, Chidiac J. TAMRAD: a GINECO randomized phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI). Cancer Res 2010, 70(Suppl 2). Abstract S1-6.
    • (2010) Cancer Res , vol.70 , Issue.SUPPL. 2
    • Bachelot, T.1    Bourgier, C.2    Cropet, C.3    Guastalla, J.-P.4    Ferrero, J.-M.5    Leger-Falandry, C.6    Soulie, P.7    Eymard, J.-C.8    Debled, M.9    Spaeth, D.10    Legouffe, E.11    Delozier, T.12    El Kouri, C.13    Chidiac, J.14
  • 14
    • 60549089850 scopus 로고    scopus 로고
    • Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen
    • 10.1158/0008-5472.CAN-08-0857, 2644349, 19190349
    • Sabnis G, Schavowitz A, Goloubeva O, Macedo LF, Brodie A. Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen. Cancer Res 2009, 69:1416-1428. 10.1158/0008-5472.CAN-08-0857, 2644349, 19190349.
    • (2009) Cancer Res , vol.69 , pp. 1416-1428
    • Sabnis, G.1    Schavowitz, A.2    Goloubeva, O.3    Macedo, L.F.4    Brodie, A.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.